Medicine
NYPOZI txid 300 mcg/300 ug injection
NYPOZI txid 300 mcg/300 ug injection is a prescription medicine containing Filgrastim for intravenous, subcutaneous use, marketed by Tanvex BioPharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store NYPOZI in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original…
Key facts
- Active ingredient (INN)
- Filgrastim
- Brand
- NYPOZI txid
- Strength
- 300 mcg/300 ug
- Dosage form
- Injection
- Route
- Intravenous, subcutaneous
- Packs
- 1 syringe, 10 syringes and 1 more
- Marketing authorisation holder
- Tanvex BioPharma
- Manufacturer
- Tanvex BioPharma
- Origin register
- US FDA, United States
- Storage
- Store NYPOZI in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Prior to injection‚ NYPOZI may be allowed to reach room temperature for a maximum of 24 hours.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L03AA02 Filgrastim
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 September 2025
- Identifiers
- RxCUI 2700369, 2700376, 2700378 +1DailyMed set ID 89092bb8-6a20-e23e-e053-2a95a90aa750NDC 72374-101, 72374-102Application BLA761126
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / 300 ug in 1 syringe, glass | 72374-101-01 | Tanvex BioPharma | 23 September 2025 |
| 10 syringe, glass in 1 carton / 300 ug in 1 syringe, glass | 72374-101-10 | Tanvex BioPharma | 23 September 2025 |
| 1 syringe, glass in 1 carton / 480 ug in 1 syringe, glass | 72374-102-01 | Tanvex BioPharma | 23 September 2025 |
| 10 syringe, glass in 1 carton / 480 ug in 1 syringe, glass | 72374-102-10 | Tanvex BioPharma | 23 September 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Filgrastim 300 mcg/300 ug injection.
Other strengths and forms of Filgrastim
Clinical summary
Filgrastim is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. MedsAcross supplies Filgrastim for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about FilgrastimFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- NEUPOGEN prescribing information (Amgen) · U.S. National Library of Medicine, DailyMed
- Accofil: European public assessment report (EPAR) · European Medicines Agency
- Filgrastim Hexal: European public assessment report (EPAR) · European Medicines Agency
Need NYPOZI txid 300 mcg/300 ug injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.